Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

Watch on Radcliffe Cardiology: *1f1xc3s*_ga*MTE1NzYxMzg0NC4xNjYxNTg2ODk0*_ga_T874FCJ3LG*MTY2MTY4MDE4NS4xMy4wLjE2NjE2ODAxOTAuMC4wLjA.&utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-6605&utm_content=esc_alexander

Dr John H P Alexander (Duke University Medical Center, US) joins us to share the latest data from the PACIFIC-AMI trial (NCT04304534).

This multicenter, randomized, placebo-controlled, double-blind and dose-finding phase 2 study assessed the efficacy and safety of asundexian (Bayer), an oral FXIa inhibitor on top of dual antiplatelet therapy (ASA + P2Y12 inhibitor) in patients following acute myocardial infarction. The trial enrolled 1,592 patients from 14 countries.

Questions
1. What is the existing evidence on FXIa inhibitors in secondary prevention?
2. What is the mechanism of action of asundexian and how does it differ from rivaroxaban?
3. What is the study design and what was the eligibility criteria?
4. What are the key findings?
5. What are next in for the PACIFIC trials?

Recorded on-site at ESC Congress 22, Barcelona.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Чтобы скачать видео "ESC 2022: PACIFIC-AMI: Asundexian on Top of DAPT After Acute Myocardial Infarction | Dr Alexander" передвинте ползунок вправо